A randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of tegaserod in patients from China with chronic constipation

Table 3 Incidence of most frequent AEs, regardless of relationship to study drug (safety population)

Adverse event	Tegaserod 6 mg b.i.d.(n = 303) (%)	Placebo(n = 303) (%)
Diarrhea	11 (3.6)	5 (1.7)
Abdominal pain	5 (1.7)	5 (1.7)
Nasopharyngitis	1 (0.3)	7 (2.3)
Transaminases increased	3 (1.0)	1 (0.3)
Nausea	1 (0.3)	3 (1.0)
Abdominal distension	3 (1.0)	0
Dizziness	2 (0.7)	0
Leukopenia	1 (0.3)	1 (0.3)
Urinary tract inflammation	1 (0.3)	1 (0.3)
Abdominal pain upper	0	2 (0.7)